Hypoxia imaging for treatment planing with the novel radiopharmaceutical 18F-fluoroazomycinarabinoside (FAZA) in cervical cancer-a pilot study.

M. Schütz; S. Kommata; Peter Angelberger; R. Schön; Robert Dudczak; Kurt Kletter; B. Bachtiary; G. Karanikas

Hypoxia imaging for treatment planing with the novel radiopharmaceutical 18F-fluoroazomycinarabinoside (FAZA) in cervical cancer-a pilot study.

M. Schütz
, S. Kommata
, Peter Angelberger
, R. Schön
, Robert Dudczak
, Kurt Kletter
, B. Bachtiary
, G. Karanikas

Medical University of Vienna

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Originalsprache	Englisch
Seitenumfang	1
Fachzeitschrift	European Journal of Nuclear Medicine and Molecular Imaging
Volume	34
Issue	2
Publikationsstatus	Veröffentlicht - 2007

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Research Field

Biosensor Technologies

Diese Publikation zitieren

@article{d362e1d6b979458783341752552963c8,

title = "Hypoxia imaging for treatment planing with the novel radiopharmaceutical 18F-fluoroazomycinarabinoside (FAZA) in cervical cancer-a pilot study.",

author = "M. Sch{\"u}tz and S. Kommata and Peter Angelberger and R. Sch{\"o}n and Robert Dudczak and Kurt Kletter and B. Bachtiary and G. Karanikas",

year = "2007",

language = "English",

volume = "34",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Hypoxia imaging for treatment planing with the novel radiopharmaceutical 18F-fluoroazomycinarabinoside (FAZA) in cervical cancer-a pilot study.

AU - Schütz, M.

AU - Kommata, S.

AU - Angelberger, Peter

AU - Schön, R.

AU - Dudczak, Robert

AU - Kletter, Kurt

AU - Bachtiary, B.

AU - Karanikas, G.

PY - 2007

Y1 - 2007

M3 - Article

SN - 1619-7070

VL - 34

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 2

ER -